Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 12/13 Goblet PC patients had Stage IV metastatic (M1) cancer

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Dec 06, 2022 2:58pm

154 Views

Post# 35154190

RE:RE:RE:RE:12/13 Goblet PC patients had Stage IV metastatic (M1) cancer

Sorry. I get it know. GOBLET To be Stage IV, it has to have gone to another organ not just outside which would be Stage 3. 93 per cent metastatic, and most, 63 per cent I think to the liver. Roche seems to know the liver. There must be several firms looking at this.

Just stand bag and think big.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand